Bebtelovimab, alone or together with bamlanivimab and etesevimab, as a broadly neutralizing monoclonal antibody treatment for mild to moderate, ambulatory COVID-19

Michael Dougan, Masoud Azizad, Peter Chen, Barry Feldman, Matthew Frieman, Awawu Igbinadolor, Princy Kumar, Jason Morris, Jeffrey Potts, Lauren Baracco, Lisa Macpherson, Nicole L. Kallewaard, Dipak R. Patel, Matthew M. Hufford, Linda Wietecha, Emmanuel Chigutsa, Sarah L. Demmon, Bryan E. Jones, Ajay Nirula, Daniel M. Skovronsky, Mark Williams, Robert L. Gottlieb
doi: https://doi.org/10.1101/2022.03.10.22272100
Back to top
Posted March 12, 2022.
Download PDF

Supplementary Material

Data/Code
Email
Bebtelovimab, alone or together with bamlanivimab and etesevimab, as a broadly neutralizing monoclonal antibody treatment for mild to moderate, ambulatory COVID-19
Michael Dougan, Masoud Azizad, Peter Chen, Barry Feldman, Matthew Frieman, Awawu Igbinadolor, Princy Kumar, Jason Morris, Jeffrey Potts, Lauren Baracco, Lisa Macpherson, Nicole L. Kallewaard, Dipak R. Patel, Matthew M. Hufford, Linda Wietecha, Emmanuel Chigutsa, Sarah L. Demmon, Bryan E. Jones, Ajay Nirula, Daniel M. Skovronsky, Mark Williams, Robert L. Gottlieb
medRxiv 2022.03.10.22272100; doi: https://doi.org/10.1101/2022.03.10.22272100
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area